<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(6)</volume><submitter>Beaujean O</submitter><funding>Erasmus Traineeship</funding><funding>Ögonfonden (SE)</funding><funding>Karolinska Institutet</funding><funding>Regnérs Foundation for Research in Eye Diseases</funding><funding>Cronqvist Foundation</funding><pubmed_abstract>&lt;h4>Purpose&lt;/h4>To assess iris neovascularization by uveal puncture of the mouse eye and determine the role of angiogenic factors during iris neovascularization.&lt;h4>Methods&lt;/h4>Uveal punctures were performed on BalbC mouse eyes to induce iris angiogenesis. VEGF-blockage was used as an anti-angiogenic treatment, while normoxia- and hypoxia-conditioned media from retinal pigment epithelium (RPE) cells was used as an angiogenic-inducer in this model. Iris vasculature was determined in vivo by noninvasive methods. Iris blood vessels were stained for platelet endothelial cell adhesion molecule-1 and vascular sprouts were counted as markers of angiogenesis. Expression of angiogenic and inflammatory factors in the puncture-induced model were determined by qPCR and western blot.&lt;h4>Results&lt;/h4>Punctures led to increased neovascularization and sprouting of the iris. qPCR and protein analysis showed an increase of angiogenic factors, particularly in the plasminogen-activating receptor and inflammatory systems. VEGF-blockage partly reduced iris neovascularization, and treatment with hypoxia-conditioned RPE medium led to a statistically significant increase in iris neovascularization.&lt;h4>Conclusions&lt;/h4>This study presents the first evidence of a puncture-induced iris angiogenesis model in the mouse. In a broader context, this novel in vivo model of neovascularization has the potential for noninvasive evaluation of angiogenesis modulating substances.</pubmed_abstract><journal>PloS one</journal><pagination>e0180235</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5489193</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A novel in vivo model of puncture-induced iris neovascularization.</pubmed_title><pmcid>PMC5489193</pmcid><pubmed_authors>Andre H</pubmed_authors><pubmed_authors>Beaujean O</pubmed_authors><pubmed_authors>Locri F</pubmed_authors><pubmed_authors>Kvanta A</pubmed_authors><pubmed_authors>Aronsson M</pubmed_authors></additional><is_claimable>false</is_claimable><name>A novel in vivo model of puncture-induced iris neovascularization.</name><description>&lt;h4>Purpose&lt;/h4>To assess iris neovascularization by uveal puncture of the mouse eye and determine the role of angiogenic factors during iris neovascularization.&lt;h4>Methods&lt;/h4>Uveal punctures were performed on BalbC mouse eyes to induce iris angiogenesis. VEGF-blockage was used as an anti-angiogenic treatment, while normoxia- and hypoxia-conditioned media from retinal pigment epithelium (RPE) cells was used as an angiogenic-inducer in this model. Iris vasculature was determined in vivo by noninvasive methods. Iris blood vessels were stained for platelet endothelial cell adhesion molecule-1 and vascular sprouts were counted as markers of angiogenesis. Expression of angiogenic and inflammatory factors in the puncture-induced model were determined by qPCR and western blot.&lt;h4>Results&lt;/h4>Punctures led to increased neovascularization and sprouting of the iris. qPCR and protein analysis showed an increase of angiogenic factors, particularly in the plasminogen-activating receptor and inflammatory systems. VEGF-blockage partly reduced iris neovascularization, and treatment with hypoxia-conditioned RPE medium led to a statistically significant increase in iris neovascularization.&lt;h4>Conclusions&lt;/h4>This study presents the first evidence of a puncture-induced iris angiogenesis model in the mouse. In a broader context, this novel in vivo model of neovascularization has the potential for noninvasive evaluation of angiogenesis modulating substances.</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017</publication><modification>2024-10-19T10:30:22.85Z</modification><creation>2019-03-27T02:48:49Z</creation></dates><accession>S-EPMC5489193</accession><cross_references><pubmed>28658313</pubmed><doi>10.1371/journal.pone.0180235</doi></cross_references></HashMap>